CD63 and neoplasm: Moreover, SP-IRIS demonstrated the presence of EVs that were double-positive for CD9, CD63, and CD81 and negative for the platelet marker CD41, which indicated low contamination of blood-derived EVs in the tumor EV isolates (Figure 2C).